Effect of Cocoa Consumption in Cardiovascular and Immune Parameters
This study has been terminated.
(Difficulties with the patient recruitment)
Sponsor:
Universidad de Antioquia
Information provided by (Responsible Party):
Monica Lucia Giraldo, Universidad de Antioquia
ClinicalTrials.gov Identifier:
NCT01496235
First received: November 24, 2011
Last updated: December 16, 2011
Last verified: December 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Arterial hypertension is one of the most preventable risk factors for stroke, cardiovascular and renal disease. Cocoa is rich in a subclass of flavonoid called flavanol this increase nitric oxide production and is involved in controlling blood pressure.
| Condition | Intervention |
|---|---|
|
Arterial Hypertension |
Dietary Supplement: Dark chocolate Dietary Supplement: White chocolate |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Randomized Clinical Trial of the Effect of Cocoa Consumption in Cardiovascular and Immune Parameters in Colombian Patients With Newly Diagnosed Stage 1 Arterial Hypertension |
Resource links provided by NLM:
Further study details as provided by Universidad de Antioquia:
Primary Outcome Measures:
- Change in diastolic blood pressure [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]Measurement of the diastolic blood pressure with the ambulatory blood pressure monitoring
Secondary Outcome Measures:
- Change in systolic blood pressure [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]Measurement of the systolic blood pressure with the ambulatory blood pressure monitoring
- Change in total cholesterol [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
- Change in low density lipoprotein cholesterol [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
- Change in high density lipoprotein cholesterol [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
- Change in triglycerides levels [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
- Change in hs-CRP [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
- Change in IL-1 beta levels [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
- Change in IL-2 levels [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
- Change in tumor necrosis factor alpha levels [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
- Change in flow mediated dilatation of the brachial artery [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
| Enrollment: | 69 |
| Study Start Date: | July 2009 |
| Study Completion Date: | July 2011 |
| Primary Completion Date: | July 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Dark chocolate
Presence of 70% cocoa solids
|
Dietary Supplement: Dark chocolate
Each chocolate bar provided 210 calories represented in 25 grams of carbohydrates, 3 g of proteins, 18 g of total fat and the presence of 70% cocoa solids
|
| Placebo Comparator: White chocolate |
Dietary Supplement: White chocolate
Each chocolate bar provided 230 calories represented in 28 grams of carbohydrates, 3 g of proteins, 18 g of total fat, without the presence of 70% cocoa solids
|
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age: 18 - 65 years old
- Resides in Medellín City
- Attached from the contributive regimen of Colombian Health System
- Essential Arterial Hypertension, stage I. Diagnosis less than 3 months.
- Medically indicated non-pharmacological therapy.
- Voluntary desire to consume 50 grams of chocolate per day for 12 weeks.
- Voluntary desire to participate in the trial and sign informed consent.
Exclusion Criteria:
- Suspect of secondary hypertension
- Suspect of injury in target organ
- Presence of diabetes mellitus
- BMI (Body Mass Index) major or equal to 30
- Present smoker or with less than four weeks of abstinence of tobacco
- Consume antiplatelet substances
- Regular consumption of antioxidants, multivitamins, anti-inflammatory medications, drugs for nasal congestion and sibutramine
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01496235
Locations
| Colombia | |
| Sede Investigaciones Universitarias, Universidad de Antioquia | |
| Medellín, Antioquia, Colombia | |
Sponsors and Collaborators
Universidad de Antioquia
Investigators
| Principal Investigator: | Monica L Giraldo, PhD | Universidad de Antioquia |
More Information
Publications:
| Responsible Party: | Monica Lucia Giraldo, Principal Investigator, Universidad de Antioquia |
| ClinicalTrials.gov Identifier: | NCT01496235 History of Changes |
| Other Study ID Numbers: | Cacao I |
| Study First Received: | November 24, 2011 |
| Last Updated: | December 16, 2011 |
| Health Authority: | Colombia: National Institutes of Health |
Additional relevant MeSH terms:
|
Hypertension Vascular Diseases Cardiovascular Diseases |
ClinicalTrials.gov processed this record on June 17, 2013